Abstract
Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil, about 87% of lung cancer patients were diagnosed at stages III/IV between 2000-2014. The availability of newer treatment options, such as tyrosine kinase inhibitors and immunotherapy, have changed patient management in Brazil while potentially improving clinical outcomes, however, few real world data has been published since then. This study aims to evaluate NSCLC stage III/IV patients’ journey in the Brazilian supplementary healthcare system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
